LTTS’ shares saw a 1.10 per cent increase following the announcement of a collaboration with NVIDIA. The collaboration aims to introduce a Gen AI and advanced software-defined architecture for medical imaging in endoscopy. This software-defined architecture, developed by LTTS and NVIDIA, is a scalable platform that serves as a decision-making tool for the medical sector. It features an image processing pipeline for noise reduction, edge and contrast enhancement, texture and color improvement, and speckle correction, enhancing visualization for image processing and AI-based decision-making support, particularly in polyp detection and classification.
Shanker Trivedi, Senior Vice President of Enterprise Business at NVIDIA, expressed that the combination of LTTS’ expertise in medical device development and NVIDIA’s full-stack edge AI computing platform is valuable for the medical technology industry. It expedites the development of AI-enabled, software-defined medical devices. Following the announcement, LTTS’ shares were up by 1.10 per cent to ₹4,502.90 at 11.40 am on the BSE.